ArticleJournal of human hypertension2022
Hypertension-mediated organ damage and established cardiovascular disease in patients with hypertension: the China Hypertension Survey, 2012-2015.
Article in Journal of human hypertension, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Contrastive Machine Learning to Quantify Hypertensive Multiorgan Damage and Identify New Disease Phenotypes: A Multinational Multimodal Study.Circulation · 2026Article
- Sex-dependent differences in mitochondrial protein acetylation in metabolic condition, oxidative stress, vascular dysfunction, hypertension, and cardiovascular disease.Clinical science (London, England : 1979) · 2026Review
- Life's Essential 8-Defined Cardiovascular Health and Mortality Risk in Cardiovascular-Kidney-Metabolic Health Stages 0-4: A Cohort Study.Journal of epidemiology and global health · 2026Article
- Investigation Patterns and the Apparent Epidemiology of Hypertension-Mediated Organ Damage.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Diagnostic Testing Patterns Influence the Detected Burden of Hypertension-Mediated Organ Damage in Hospitalized Hypertensive Patients.Journal of clinical hypertension (Greenwich, Conn.) · 2026Article
- Stroke risk in patients with hypertensive retinopathy: a systematic review and meta-analysis.BMJ neurology open · 2026Article
- Prescribing characteristics and guideline concordance of antihypertensive western and Chinese patent medicine in Internet hospitals in China: a cross-sectional study.Frontiers in pharmacology · 2025Article
- Ambulatory blood pressure monitoring profiles in Asia.Journal of clinical hypertension (Greenwich, Conn.) · 2024Review
- Hypertensive organ damage: the vulnerable heart of women.Journal of human hypertension · 2023Article
- LncRNA-GAS5 and β-Catenin as Independent Predictors of Asymptomatic Organ Damage in Nondiabetic Hypertensive Patients.ACS omega · 2023Article
- The Depiction of Hypertension in Heart Imaging Examinations: An Up-to-Date Review of the Evidence.Vascular health and risk management · 2023Review
- Reliability and Validity of the Amharic Version of the Hill-Bone Adherence to High Blood Pressure Therapy Scale Among Ethiopian Hypertensive Patients.Patient preference and adherence · 2023Article
- The Efficacy Mechanism of Epigallocatechin Gallate against Pre-Eclampsia based on Network Pharmacology and Molecular Docking.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Association between Cardio-Ankle Vascular Index and Masked Uncontrolled Hypertension in Hypertensive Patients: A Cross-Sectional Study.Journal of healthcare engineering · 2022Article
- Epidemiology of atrial fibrillation and risk of CVD mortality among hypertensive population: A prospective cohort study in Northeast China.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
- Commented on by
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is a major health burden worldwide. However, there is limited data on the status of hypertension-mediated organ damage (HMOD) and established cardiovascular (CV) disease in Chinese hypertensive patients. The aim of this study is to determine the prevalence of HMOD and established CV disease in a nationally representative population in China. A stratified multistage random sampling method was used in the China Hypertension Survey and 21,243 participants aged 35 or older were eligible for analysis in this study. For each participant, the demographic information and a self-reported medical history were acquired. Blood pressure was measured with the electronic device 3 times on the right arm, supported at heart level, after the participant was sitting at rest for 5 min. Samples of blood and urine were tested. 2-D and Doppler echocardiography were used to assess the heart's function and structures. Sampling weights were calculated based on the 2010 China population census data. Overall, the weighted prevalence of asymptomatic HMOD was 22.1%, 28.9%, 23.1%, 6.4%, and 6.2% for wide pulse pressure, left ventricular hypertrophy, microalbuminuria, chronic kidney disease, and abnormal ankle-brachial index, respectively. For the established CV disease, the weighted prevalence was 1.8%, 1.3%, 2.0%, and 1.1% for stroke, coronary artery disease, heart failure, and atrial fibrillation, respectively. The prevalence of asymptomatic HMOD and established CV disease was greater with higher blood pressure level (P < 0.05), rather than ankle-brachial index. Compared to those with uncontrolled hypertension, the prevalence of asymptomatic HMOD was lower in patients with controlled hypertension. In summary, the prevalence of HMOD in Chinese people aged 35 or older was very common, indicating a substantial future burden of both morbidity and mortality from hypertension in China. Clinical trial registration number: ChiCTR-ECS-14004641.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.